#POLB Poolbeg Pharma PLC – POLB 001 Patent Granted in Korea March 20, 2025 – Posted in: Poolbeg Pharma (POLB)

20 March 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that the Korean Intellectual Property Office has notified the Company of its official decision to grant Poolbeg’s Republic of Korea Immunomodulator II patent application providing protection to POLB 001 for the treatment of severe influenza to December 2038.   POLB 001 is a potent and selective p38 MAP…

Continue reading